VANCOUVER, BRITISH COLUMBIA--(Marketwire - Aug. 7, 2007) - Allon Therapeutics Inc. (TSX:NPC), The Neuro Protection CompanyTM, announced today that in collaboration with TURNS (Treatment Units for Research on Neurocognition and Schizophrenia) and with support from the National Association for Research in Schizophrenia and Affective Disorders (NARSAD) they will add an imaging-biomarker component to the current Phase II efficacy trial evaluating AL-108 as a treatment for schizophrenia-related cognitive impairment. Three different imaging techniques will be used to investigate whether AL-108 treatment results in a change in the brain structures affected by schizophrenia. TURNS believes that based on the mechanism of action of Allon's product AL-108, structural changes in the brain should correlate with an improvement in cognitive function.
